156 - Overcoming Scale-Up Challenges in Pharmaceutical Process Development (S11E6)

You know, we often hear about these amazing breakthroughs
in drug discovery, right? A new molecule looks
great in the lab. Yeah, that eureka molecule.
Exactly. But getting from that tiny lab success
to the medicine you actually pick up, that's
a whole other story. A much longer, much more
complex story. And one of the really critical
pinch points is scaling up. taking that lab process
and making it work reliably, huge scale. That's
where the real engineering and science challenges
often kick in. Yeah. And that's what we're diving
into today. The common hurdles in that pharmaceutical
scale up phase. Right. And for you, the learner
who wants the key insights without getting lost
in the weeds, think of this as your guide to
the main obstacles. We've looked through various
sources on drug development, manufacturing. Can
really pull out the essentials on these scale
up challenges. Our mission. Shine a light on
these common issues. Talk about why understanding
the deep science, the mechanistic evaluation,
is so vital. And also touch on why sometimes
you don't hear much about the scale of details
in the success stories. OK, let's get into it.
That first big leap, small lab gear to massive
industrial kit. It sounds simple, just bigger,
but I guess it's not. Oh, not at all. It's a
fundamental shift. What happens nicely in a little
flask behaves, well, very differently in a giant
stainless steel reactor. How so? You're dealing
with completely different scales of, say, mixing.
Getting everything evenly blended in a thousand
liter tank is way harder than stirring a beaker.
Right, like stirring coffee versus stirring a
swimming pool. Exactly. And that affects reactions.
Same goes for heat transfer, getting heat in
or out efficiently. And mass transfer, how things
move around in the mixture. These physical factors
change drastically. And that change can cause
problems? Big problems. It can affect reaction
speed, yield, and critically, the formation of
unerranted byproducts or impurities. Ah, impurities.
I was going to ask about that. Keeping the drug
pure when you make tons of it must be a huge
focus. It's absolutely paramount. An impurity
that's barely detectable at the gram scale in
the lab. It can become a significant issue when
you're producing kilograms or tons. Because even
a tiny percentage adds up to a lot. Precisely.
That's why impurity qualification is such a big
deal. You have to know what impurities are there,
how much, and critically prove they're safe at
those levels. Our sources really stress this.
So a process that looked super clean initially
might reveal some hidden issues when you blow
it up to size. It can happen. Which leads to
the next point. Process robustness. I mean. Meaning,
how reliable and repeatable is the process? Does
it work consistently, batch after batch, even
with the slight variations that inevitably happen
in large -scale manufacturing? Because perfect
lab conditions are hard to replicate in a factory.
Very hard. Temperature fluctuations, slight differences
in mixing energy, tiny variations in raw materials.
A process needs to be robust enough to handle
these without the quality suffering. Reproducibility
is key. And you mentioned raw materials. I imagine
just getting enough stuff is a challenge, let
alone ensuring it's all the same quality. You've
hit on another major hurdle, moving from buying
small amounts of highly pure lab chemicals to
sourcing industrial quantities. Suppliers might
differ. Batch -to -batch variability within a
supplier can exist. And this bumps up against
regulations, I assume. Directly. GMP good manufacturing
practice requirements are very strict about controlling
and testing starting materials. You need rigorous
checks on everything coming in. It sounds like
a massive logistical and quality control exercise
even before you start the main process. It really
is. And then there's controlling the process
itself while it's running. Right. Monitoring
huge reactors must be way more complex than watching
a small flask. Absolutely. Keeping parameters
like temperature, pressure, pH consistent throughout
a massive volume requires sophisticated process
control and monitoring systems. Is that where
things like continuous manufacturing come in?
I've heard about that. That's certainly part
of the drive towards it. Continuous processing,
more like an assembly line, can offer tighter
control and more real time monitoring compared
to traditional large batch methods. It could
potentially mitigate some of these scale up control
issues. Interesting. OK, another practical thing.
Cleaning. How do you ensure these enormous vessels
are perfectly clean between batches? Contamination
seems like a huge risk. Huge risk and huge focus.
Cleaning validation is a major part of GMP, like
the FDA's CFR Title 21 Part 211 rules. You need
validated procedures to prove equipment is cleaned
effectively to prevent any carryover or microbial
contamination. Because any little bit left behind
could ruin the next massive batch. Exactly. Safety
and quality depend on it. And one last challenge
area, the actual final medicine, the formulation.
Does making it in bulk affect things like stability
or how it works in the body? It definitely can.
The way ingredients are mixed, dried, or compressed
on a large scale might differ from the lab. This
could potentially affect the drug's stability
over time, or its bioavailability, how much actually
gets absorbed. So you might need to tweak the
recipe, essentially. Sometimes, yes. Formulation
adjustments might be needed. And if those changes
are significant, you might need to prove the
scaled -up version still behaves the same way
in the body through bioequivalent studies. Wow.
Okay, so it's clear scaling up is far from simple
multiplication. It introduces a whole host of
new scientific and engineering problems. Absolutely.
Which brings us back to that term, mechanistic
evaluation. Right. You said understanding the
mechanism is crucial. What does that really mean
in this context? It means going beyond just knowing
that a process step works and understanding why
it works. What are the underlying physical principles,
the chemical reaction pathways, the kinetics,
the thermodynamics? So the deep science behind
the recipe steps. Exactly. Like a chef understanding
why adding acid tenderizes meat. not just knowing
that the recipe says to add lemon juice. Okay,
I get that. And why is that deep understanding
so vital for scale -up? Because it allows you
to predict how the process will behave when you
change the scale. If you understand how mixing
affects reaction rate, you can make informed
decisions about the type of impeller and mixing
speed needed in the large reactor. Instead of
just guessing or endless trial and error? Precisely.
Trial and error at large scale is incredibly
expensive. time -consuming and risky. A mechanistic
understanding provides a rational basis for scale
-up design and troubleshooting. And does it help
with those specific issues like impurities and
consistency? Definitely. If you understand the
reaction mechanism, you can often pinpoint where
impurities are likely to form and adjust conditions,
temperature, pressure, region addition, to minimize
them. And it helps identify the truly critical
process parameters, the factors that really impact
final product quality. Understanding the mechanism
helps you focus your control strategy on what
matters most. That's fundamental to the quality
by design or QBD approach. Building quality in
from the start based on science. That's the idea.
It really sounds like that deep scientific grasp
is the bedrock for navigating scale -up successfully.
Which makes it interesting that, as you noted
earlier, we don't always hear a lot about these
scale -up journeys in published case studies.
Why might that be? Yeah, it's an interesting
observation. There are probably a few reasons.
One big one is likely the proprietary nature
of this information. Trade secrets, basically.
Exactly. How a company successfully scaled up
its unique process. That's valuable intellectual
property. Sharing detailed scale -up data and
solutions could give competitors insights they
wouldn't otherwise have. Makes sense. Keep your
competitive advantage. Right. Another factor
might be the focus of many publications. Often,
the primary story is about the drug discovery
itself. The clinical trial results proving safety
and efficacy. The headline news? Kind of. The
manufacturing details, while critical, might
be seen as, well... less scientifically novel
or exciting for a high impact journal focused
on clinical outcomes. So the how we made it gets
less attention than, look, it works. Sometimes,
yes. And there can also be a bit of a divide
maybe between the discovery research and the
process development or chemical engineering disciplines
involved in scale up. They might publish in different
circles or focus on different aspects. So different
communities almost. Potentially. But this lack
of visibility around scale -up challenges and
solutions, it does have implications. How so?
Well, if experiences aren't shared, both the
wins and, perhaps more importantly, the failures
and the lessons learned, then the broader community
might miss out. Others might end up reinventing
the wheel or hitting the same roadblocks. Exactly.
It can slow down overall progress. More transparency,
where possible and appropriate, about scale -up
experiences could arguably accelerate drug development.
and improve manufacturing efficiency across the
industry. Sharing non -proprietary insights,
common pitfalls, general strategies, that could
be really beneficial. It sounds like a more open
dialogue about the nuts and bolts of getting
from lab to market could lift all boats. I think
there's a strong argument for that, yes. Okay,
so, wrapping this up. If we boil it down, what
are the absolute key takeaways for the learner
today? First, scaling up pharmaceutical processes
is complex. It involves navigating challenges
with equipment translation, ensuring quality
and consistency, maintaining process robustness,
managing raw materials, implementing controls,
ensuring sterility, and potentially reformulating.
It's not just bigger. Got it. Challenge number
one, it's hard. Yes. Second takeaway, a deep
mechanistic understanding of the science behind
the process is absolutely vital. It's the key
to predicting issues, solving problems efficiently,
and designing robust large -scale processes.
So know your science. Know your science. And
third, while scale -up details aren't always
widely shared, perhaps for valid reasons, more
openness about the challenges and learnings could
really help the whole field move forward faster.
Great summary. And understanding these points
really gives you a much fuller picture of drug
development, doesn't it? It highlights the incredible
complexity behind ensuring we have reliable,
high -quality medicines available. Absolutely.
It's a critical, often underappreciated part
of the journey. Which leads to a final thought
for the learner to maybe chew on. As manufacturing
tech keeps advancing, we mentioned continuous
processing. For instance, how might these traditional
scale -up challenges change? Will they shrink
or just transform into different kinds of challenges
in the future? That's a great question. How will
new technologies reshape this landscape? Definitely
something to watch as pharmaceutical manufacturing
continues to evolve.